The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Open accessAbstract
The ability to predict the future behavior of an individual cancer is crucial for precision cancer medicine. The discovery of extensive intratumor heterogeneity and ongoing clonal adaptation in human tumors substantiated the notion of cancer as an evolutionary process. Random events are inherent in evolution and tumor spatial structures hinder the efficacy of selection, which is the only deterministic evolutionary force. This review outlines how the interaction of these stochastic and deterministic processes, which have been extensively studied in evolutionary biology, limits cancer predictability and develops evolutionary strategies to improve predictions. Understanding and advancing the cancer predictability horizon is crucial to improve precision medicine outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 2×
“(B) Changes of the mutational processes operating in a cancer [19,26] can alter the accessibility of the fitness peaks but not the topology of the fitness landscape.”
BackgroundIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 4×
“carcinogenesis [26] but also late during cancer progression [9].”
BackgroundInfluentialSelf-citationNowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · cited 1×
“Alternative EGFR mutations, MET proto-oncogene or erb-b2 receptor tyrosine kinase 2 (ERBB2) amplification or non-pathway-dependent resistance through transformation into small-cell lung cancers were observed less frequently in biopsies from resistant tumors [46].”
BackgroundMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414 · cited 1×
“Fusion of two chromosome ends fostering cycles of chromosome breakage and fusion during mitosis [23] or catastrophic ‘chromothripsis’ events leading to massive genomic rearrangements within a single cell division [24] are two examples.”
BackgroundProspective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
“It remains an open question whether distinct clinical behaviors can be observed depending on the mode of tumor evolution, or whether the occurrence of neutral evolution and drift may limit the ability to predict a tumor’s next step (Lipinski et al., 2016).”
Resolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 653
Self-citationLife and death of circulating cell-free DNA
Kustanovich, A., Schwartz, R., Peretz, T., & Grinshpun, A. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1598759 · Cited by 606
Genomic and phenotypic heterogeneity in prostate cancer
Haffner, M. C., Zwart, W., Roudier, M. P., True, L. D., Nelson, W. G., Epstein, J. I., De Marzo, A. M., Nelson, P. S., & Yegnasubramanian, S. (2021) · Nature Reviews Urology · doi:10.1038/s41585-020-00400-w · Cited by 502
Classifying the evolutionary and ecological features of neoplasms
Maley, C. C., Aktipis, A., Graham, T. A., Sottoriva, A., Boddy, A. M., Janiszewska, M., Silva, A. S., Gerlinger, M., Yuan, Y., Pienta, K. J., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.69 · Cited by 423
Self-citationInterfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Little, N., de Souza, C. P. E., Laan, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.073 · Cited by 353
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
Zhang, A., Miao, K., Sun, H., & Deng, C.-X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72534 · Cited by 352
Lässig, M., Mustonen, V., & Walczak, A. M. (2017) · Nature Ecology & Evolution · doi:10.1038/s41559-017-0077 · Cited by 343
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Faltas, B. M., Prandi, D., Tagawa, S. T., Molina, A. M., Nanus, D. M., Sternberg, C., Rosenberg, J., Mosquera, J. M., Robinson, B., Elemento, O., et al. (2016) · Nature Genetics · doi:10.1038/ng.3692 · Cited by 294
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
Role of imaging in the era of precision medicine
Giardino, A., Gupta, S., Olson, E., Sepulveda, K., Lenchik, L., Ivanidze, J., Rakow-Penner, R., Patel, M. J., Subramaniam, R. M., & Ganeshan, D. (2017) · Academic Radiology · doi:10.1016/j.acra.2016.11.021 · Cited by 87
Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64
“Subclonal heterogeneity allows dynamic tumor adaption and is generally a key cause of treatment failure (56).”
Background
Metadata
- Authors
- Lipinski, K. A., Barber, L. J., Davies, M. N., Ashenden, M., Sottoriva, A., & Gerlinger, M.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 2
- Issue
- 1
- Pages
- 49-63
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2259572413
- Cited by
- 248
- References
- 35
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.